OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukaemia, providing a robust, accessible,...
Read articleOGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukaemia, providing a robust, accessible, rapid turnaround test for KMT2Ar detection.
ReadThrough this partnership, SureSeq™ NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
ReadOGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
ReadImproving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
ReadEnables users to replace multiple techniques with a single streamlined NGS process for faster results.
ReadInvestment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
ReadNew NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
ReadOGT becomes Britain’s distributor for ASI cytogenetic imaging and analysis solutions, enhancing the potential of OGT’s CytoCell® FISH portfolio.
ReadCompany demonstrates complete readiness for new EU IVDR and continued confidence in its safe, reliable, high-quality products.
ReadEnhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
Read
Visit USA site
Visit Canada site
